Complementary integration of biomarkers and imaging to support shared decision making

Panelists discuss how combining biomarkers and imaging provides a more comprehensive diagnostic approach, ensuring that each tool’s strengths offset the other’s weaknesses. They reference studies showing that integrating IsoPSA with MRI leads to improved diagnostic accuracy and fewer missed clinically significant cancers.

Panelists discuss how this complementary strategy enhances patient counseling and shared decision-making. Presenting both biomarker and imaging results to patients allows for clearer communication of risk and more individualized choices regarding biopsy or continued surveillance.

Panelists discuss how real-world workflows are increasingly adapting to this dual-modality approach, reflecting growing confidence in biomarker and imaging integration. The panel anticipates that as data accumulate, such combined strategies will become routine in prostate cancer diagnostics.